Johnson & Johnson Beats Earnings, Raises Full-Year 2026 Guidance
Johnson & Johnson reported stronger-than-expected second quarter earnings on July 15th, leading the company to increase its full-year 2026 financial guidance. The healthcare giant posted quarterly sales of 25.3 billion dollars, up 6.6 percent year over year, and adjusted earnings per share of 2.90 dollars, beating analyst estimates. The company raised its full-year revenue guidance to between 100.8 and 101.4 billion dollars with a 101.1 billion midpoint, and increased adjusted earnings per share guidance to between 11.60 and 11.75 dollars. CEO Joaquin Duato emphasized the company would reach the historic 100 billion dollar revenue milestone for the first time in its 140-year history. Strong growth in innovative medicines, particularly oncology drugs like Darzalex and immunology drug Tremfya which surged 72.5 percent, helped offset declines from products losing patent protection including Stelara. The company also reported improved free cash flow. Despite the beat and raised guidance, shares fell initially as some investors had already priced in positive results.
Key facts
- Q2 2026 revenue reached 25.31 billion dollars, up 6.6 percent year over year and above estimates of 25.05 billion
- Adjusted EPS of 2.90 dollars beat consensus estimate of 2.85 dollars
- Full-year 2026 revenue guidance raised to 100.8 to 101.4 billion dollars with 101.1 billion midpoint, representing first time exceeding 100 billion dollars in company history
- Adjusted EPS guidance increased to 11.60 to 11.75 dollars with 11.68 midpoint, up 13 cents from prior guidance
- Innovative Medicine segment grew 7.8 percent to 16.38 billion dollars, with Tremfya reaching 2 billion in quarterly sales up 72.5 percent
- Abiomed heart pump sales declined 2 percent due to physician caution following UK clinical study
- Free cash flow reached 8.7 billion year to date, up from 6.21 billion in prior year
- Company now projects double-digit revenue growth by end of decade
Limits of this briefing
Most sources were business and financial publications; limited coverage from major mainstream or opinion-oriented outlets that might represent diverse political perspectives. Stock market reaction was muted or negative despite strong results, suggesting market expectations may have differed from company performance.
Sources
- CNBC: J&J quarterly earnings beat Wall Street estimates on strength of medicines unit Centre
- Reuters (via Quartz): Johnson & Johnson posts Q2 2026 earnings beat on medicines unit strength Centre
- Investing.com: Johnson & Johnson Q2 2026 slides: $100B revenue target in sight Centre
- The Globe and Mail: Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat Centre
- Yahoo Finance: Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance Centre